A web-blog (formerly known as Stu's Views and MS News), now published by MS Views and News, a patient advocacy organization. The information on this blog helps to Empower those affected by Multiple Sclerosis globally, with education, information, news and community resources.
~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Thursday, January 24, 2013
Biogen Sees Positive Results From Study of Potential Multiple Sclerosis Treatment
By Dow Jones Business News, January 24, 2013,
By Saabira Chaudhuri
Biogen Idec ( BIIB ) said data from a late-stage trial of its potential multiple-sclerosis treatment were positive.
The biopharmaceutical company said results support peginterferon beta-1a as a potential treatment dosed every two weeks or every four weeks for relapsing-remitting multiple sclerosis.
"If approved, peginterferon beta-1a will represent an innovation that offers patients a less frequent dosing schedule of no more than 26 doses annually, as well as a significant reduction in relapses and disability progression," said Gilmore O'Neill, vice president of global neurology late stage clinical development at Biogen.
Biogen said the study's primary endpoint was met for both the two-week and four-week dose regimens. Results showed that peginterferon beta-1a also met the secondary endpoints. It noted that with both dose regimens studied the risk- benefit profile of peginterferon beta-1a appears to be favorable.
The Phase 3 study included more than 1,500 patients with RRMS and was designed to evaluate the efficacy, safety and tolerability of peginterferon beta-1a compared to placebo at one year.
Earlier this month, Biogen said its Phase 3 clinical trial for an ALS treatment didn't meet its primary goals, causing it to discontinue development of the drug for the disease.
And in October, Biogen reported its third-quarter earnings rose 13% as the biopharmaceutical company saw growth of its biggest drug, multiple-sclerosis treatment Avonex, and received a boost from a gain tied to Benlysta.
(END) Dow Jones Newswires
Copyright (c) 2013 Dow Jones & Company, Inc.